- Home
- PLX vs ENTX Comparison
PLX vs ENTX Comparison
Compare PLX & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- ENTX
- Stock Information
- Founded
- PLX 1993
- ENTX 2010
- Country
- PLX Israel
- ENTX Israel
- Employees
- PLX N/A
- ENTX N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLX Health Care
- ENTX Health Care
- Exchange
- PLX Nasdaq
- ENTX Nasdaq
- Market Cap
- PLX 79.4M
- ENTX 67.2M
- IPO Year
- PLX 1998
- ENTX 2018
- Fundamental
- Price
- PLX $1.68
- ENTX $1.66
- Analyst Decision
- PLX
- ENTX Strong Buy
- Analyst Count
- PLX 0
- ENTX 1
- Target Price
- PLX N/A
- ENTX $10.00
- AVG Volume (30 Days)
- PLX 439.0K
- ENTX 131.0K
- Earning Date
- PLX 11-14-2024
- ENTX 11-08-2024
- Dividend Yield
- PLX N/A
- ENTX N/A
- EPS Growth
- PLX N/A
- ENTX N/A
- EPS
- PLX N/A
- ENTX N/A
- Revenue
- PLX $45,667,000.00
- ENTX $99,000.00
- Revenue This Year
- PLX N/A
- ENTX N/A
- Revenue Next Year
- PLX $88.94
- ENTX N/A
- P/E Ratio
- PLX N/A
- ENTX N/A
- Revenue Growth
- PLX N/A
- ENTX 607.14
- 52 Week Low
- PLX $0.82
- ENTX $0.52
- 52 Week High
- PLX $1.90
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- PLX 74.56
- ENTX 42.82
- Support Level
- PLX $1.14
- ENTX $1.64
- Resistance Level
- PLX $1.75
- ENTX $1.80
- Average True Range (ATR)
- PLX 0.12
- ENTX 0.10
- MACD
- PLX 0.05
- ENTX -0.01
- Stochastic Oscillator
- PLX 87.29
- ENTX 39.54
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.